Your browser doesn't support javascript.
loading
Patient-reported perceptions of brexanolone in the treatment of postpartum depression: A qualitative analysis.
Salwan, Aaron; Maroney, Megan; Tremayne, Lisa.
Afiliação
  • Salwan A; Behavioral Health Clinical Pharmacy Specialist, Montefiore Nyack Hospital, Nyack, New York, salwana@montefiorenyack.org.
  • Maroney M; Associate Professor, Rutgers the State University of New Jersey, Piscataway, New Jersey.
  • Tremayne L; Director, Perinatal Mood and Anxiety Disorders Clinic, Monmouth Medical Center, Long Branch, New Jersey.
Ment Health Clin ; 12(6): 342-349, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36644587
ABSTRACT

Introduction:

Brexanolone demonstrates short-term efficacy for the treatment of postpartum depression (PPD). Postpartum depression is linked to infanticide and maternal suicide, and current treatment often fails to adequately control depressive symptoms. The purpose of this analysis is to further understand the experience(s) of women who have received brexanolone for the treatment of PPD.

Methods:

Semistructured interviews modeled after the theory of planned behavior (TPB) were conducted to assess women's perceptions of treatment for PPD with brexanolone. Women who received treatment with brexanolone at this inpatient facility were eligible to participate in this study. The TPB is often used to predict intention to perform health-related behaviors. Semistructured interviews were recorded and transcribed, and thematic analysis was conducted to identify common ideas across all interviews. Follow-up assessment of depressive and anxious symptoms was also conducted using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7), respectively.

Results:

Five of the 10 women who received treatment with brexanolone at this facility were interviewed, and common themes related to the TPB were analyzed. Attitudes toward brexanolone were favorable, and having a strong support system was a motivating factor in receiving treatment for PPD. Insurance approval, need for childcare, and poor understanding of symptoms of PPD were barriers to receiving treatment with brexanolone. Symptoms of depression and anxiety were rated as low at the time of the follow-up interview as measured by the PHQ-9 (mean 1.6, range 1 to 3) and GAD-7 (mean 2.8, range 2 to 4), respectively.

Discussion:

Brexanolone rapidly and sustainably reduced symptoms of PPD and was well-received by patients. Despite significant barriers to use, women who received treatment with brexanolone advocated for its availability as well as increased awareness of PPD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article